LEXINGTON, Mass.--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) (the “Company” or “Inotek”), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that David P. Southwell, President and Chief Executive Officer of Inotek, will present at the 2016 Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) annual meeting on Thursday, October 13, 2016, at 3:18 p.m. Central Time at the Hyatt Regency Chicago.
About Inotek Pharmaceuticals Corporation
Inotek
Pharmaceuticals is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of therapies for
glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson,
is a first-in-class selective adenosine mimetic currently in Phase 3
development. Trabodenoson was developed in Inotek’s
laboratories and is designed to restore the eye’s natural pressure
control mechanism. Additionally, the Company is evaluating the potential
for selective adenosine mimetics to address optic neuropathies and other
degenerative retinal diseases. For more information, please visit www.inotekpharma.com.
The inclusion of our website address here and elsewhere in this press
release does not include or incorporate by reference the information on
our website into this press release.
Forward-Looking Statements
This press release contains
forward-looking statements, which are subject to substantial risks,
uncertainties and assumptions. You should not place reliance on these
statements often include words such as "believe," "expect,"
"anticipate," "intend," "plan," "estimate," "seek," "will," "may" or
similar expressions. Although the Company believes that the expectations
reflected in the forward-looking statements are reasonable, the Company
cannot guarantee such outcomes. Accordingly, you should not place undue
reliance on these forward-looking statements. All such statements speak
only as of the date made, and the Company undertakes no obligation to
update or revise publicly any forward-looking statements, whether as a
result of new information, future events or otherwise.